Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
CNBC - 2024-04-09T10:45:01.000Z

Pfizer plans to file for an expanded approval of Abrysvo, which is currently approved for adults ages 60 and above and expectant mothers.

In related news

Pfizer to seek approval for RSV vaccine for people as young as 18
An RSV vaccine already used for older adults could help protect people as young as 18 who are at increased risk of the disease, drugmaker Pfizer said.
- Related Articles
- In News
- From WCVB
- 2024-04-10T01:04:00.000Z
Pfizer to seek approval for RSV vaccine for people as young as 18
An RSV vaccine already used for older adults could help protect people as young as 18 who are at increased risk of the disease, drugmaker Pfizer said.
- Related Articles
- In News
- From KSBW
- 2024-04-10T01:04:00.000Z
Accelerated aging linked to cancer risk in younger adults, research shows
By Brenda Goodman, CNN (CNN) — Researchers looking for clues about why some types of cancer are on the rise in younger adults say they’ve found an interesting lead: a connection to accelerated biological aging. Aging is the major risk for many types of cancer, meaning the older you get, the more likely you are
- Related Articles
- In News
- From KIFI
- 2024-04-07T18:00:25.000Z